Design, synthesis, and bioactivity evaluation of macrocyclic benzo[b]pyrido[4,3-e][1,4]oxazine derivatives as novel Pim-1 kinase inhibitors
- 29 June 2022
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 72, 128874
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Beijing Municipality (L212001)
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
This publication has 24 references indexed in Scilit:
- Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?Journal of Medicinal Chemistry, 2013
- A New Target for an Old Drug: Identifying Mitoxantrone as a Nanomolar Inhibitor of PIM1 Kinase via Kinome-Wide Selectivity ModelingJournal of Medicinal Chemistry, 2013
- Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumorsMolecular and Cellular Endocrinology, 2013
- Synthetic Macrocycles in Small-Molecule Drug Discovery2013
- LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug DiscoveryJournal of Chemical Information and Modeling, 2011
- Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancerInvestigational New Drugs, 2009
- Impact of CYP3A5 and MDR1(ABCB1) C3435T Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant RecipientsTransplantation Proceedings, 2005
- Pim‐1 expression in prostatic intraepithelial neoplasia and human prostate cancerThe Prostate, 2004
- Clinical Pharmacokinetics of SirolimusClinical Pharmacokinetics, 2001
- A COMPARISON OF TACROLIMUS (FK506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION AFTER CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1997